Searched for
US BIOPHARMA FUNDING
L’Oréal adds Innovist to cart; HealthQuad's new fundHappy Friday! Personal care giant L’Oreal has acquired a majority stake in Innovist in India’s biggest D2C deal. This and more in today’s E...- HealthQuad raises Rs 550 crore, eyes Rs 1,700 crore fundHealthQuad has secured Rs 550 crore for its third fund. The venture capital firm aims to raise Rs 1,700 crore to back early-growth companie...
- Global drugmakers rush to boost US presence as tariff threat loomsGlobal drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...
- Piyush Goyal meets Ernst & Young CEO, discusses India's role in global supply chainsUnion Minister Piyush Goyal said he held a meeting with Janet Truncale, Global Chair and CEO of EY, to discuss India's growing role in glob...
- Avammune’s big bet: Why the future of cancer treatment may come in a pillAs global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...
- Sun Pharma shares tumble 4% as firm closes in on $12-billion Organon acquisition. What’s spooking investors?Shares of Sun Pharmaceutical Industries fell sharply after ET reported the company had submitted a $12-billion binding offer for Organon & ...
- Sun Pharma closes in on Organon buy, gets set for $12 billion binding bidSun Pharmaceutical Industries is nearing a $12 billion acquisition of Organon & Co, marking its most significant overseas expansion. Follow...
- BIRAC fuels innovation with Rs 4,200 crore funding across 15 lakh startups and entrepreneursIndia's Biotechnology Industry Research Assistance Council, BIRAC, marked its 14th Foundation Day. It has significantly boosted India's bio...
- Piramal Pharma Q3 Results: Co reports loss as CDMO slowdown drags revenuePiramal Pharma swung to a Rs 136 crore Q3 loss as revenue fell 3%, hit by CDMO destocking, weak US biopharma funding, trade uncertainty and...
- Piramal Pharma shares in focus after USFDA issues form 483 for Kentucky unitPiramal Pharma's US facility inspection concluded with four observations from the FDA. The company expects a voluntary action indicated cla...
- VC fund HealthKois plans $400 million fund for healthcare playHealthKois is aiming at a first close at the end of this year or early 2026. The investments will be deployed over the next four years, wit...
- Syngene International sees strong momentum this fiscal year: MDSyngene International also expects business growth from its pharma clients who are keen to make up for the time that they felt they lost du...
- Unable to sell Sputnik Light stock, Stelis Biopharma requests PM Modi for procurement of jabsIn the letter written on May 13, Arun Kumar, Founder and Director of Stelis Biopharma Limited, said that after the prime minister had reque...
- Zumutor Biologics bags $6.2 million funding led by Siana CapitalThe latest round also saw participation from existing investors Accel and Bharat Innovation Fund, bringing the total capital raised by the ...
- Hetero begins Sputnik V production at Hyderabad facilityIn an interaction with the Russian president Vladimir Putin on Friday through a video conference, Hetero group’s Chairman Dr Bandi Parthasa...
- India imports 80% of its requirement of medical devices: MoS Ashwini ChoubeyThe Central Drugs Standard Control Organisation (CDSCO) is presently regulating 28 categories of notified medical devices under the provisi...
- Strides Arcolab invests in Oncobiologics Inc, acquires stakeShares of Strides Arcolab were today trading at Rs 667.60 per scrip in the morning trade on BSE, up 2.54 per cent from its previous close.
- 'Indian bio-pharma R&D spending could grow to $25 bn by 2025'India's bio-pharma sector may see a surge in R&D spending to about $25 billion in the next 15 years, according to a Boston Consulting Group...
- 'The future of biopharma in India is bright'One of the leaders in the Biopharma world, UCB is deep into research on very critical health issues. In a chat ,Charles-Antoine Janssen Man...
- Nicholas Piramal in fray for CambrexThe Bid for Cambrex, a New Jersey-based life sciences company, could become an India affair.
Load More
